Pear Therapeutics (PEAR) Stock Price, News & Analysis

Company Overview

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 66.30 million shs
• Average Volume: 7.75 million shs
• Market Capitalization: $4.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PEAR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Pear Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pear Therapeutics investors own include Meta Platforms (META), LyondellBasell Industries (LYB), AbCellera Biologics (ABCL), Atai Life Sciences (ATAI), CVS Health (CVS), uniQure (QURE) and Absci (ABSI).

Company Calendar

• Today: 1/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PEAR
• CUSIP: N/A
• CIK: 1835567
• Web: peartherapeutics.com
• Phone: 617-925-7848
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-75,490,000.00
• Net Margins: -594.70%
• Pretax Margin: -594.70%
• Return on Equity: -217.85%
• Return on Assets: -95.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.48
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $12.69 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 142,739,000
• Free Float: 98,918,000
• Market Cap: $4.17 million
• Optionable: Not Optionable
• Beta: 0.45